Enterprise Value
-24.89M
Cash
89.43M
Avg Qtr Burn
-8.167M
Short % of Float
1.63%
Insider Ownership
7.44%
Institutional Own.
21.28%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Onvansertib (monotherapy) Details Cancer, Small cell lung cancer | Phase 2 Data readout | |
Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab) Details Cancer, Metastatic colorectal cancer | Phase 2 Data readout | |
Onvansertib + nanoliposomal irinotecan (Onyvide®) (PLK1) Details Cancer, Pancreatic cancer, Solid tumor/s | Phase 2 Data readout | |
Onvansertib + decitabine (inhibitor of Polo-like Kinase 1) Details Cancer, Acute myeloid leukemia | Phase 2 Update | |
Onvansertib + Zytiga (abiraterone) Details Prostate cancer, Cancer, Castration-resistant prostate cancer | Phase 2 Update | |
Onvansertib + Paclitaxel Details Cancer, Triple-negative breast cancer | Phase 1/2 Data readout | |
Onvansertib + Second-Line Standard-of-Care (PLK1) Details Colorectal cancer , Cancer | Failed Discontinued |